Cargando…
Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease that lacks effective treatment modalities. Once patients are diagnosed with IPF, their median survival is approximately 3–5 years. PPARγ is an important target for the prevention and treatment of pulmonary fibrosi...
Autores principales: | Zeng, Qian, Zhou, Ting-ting, Huang, Wen-jie, Huang, Xiao-ting, Huang, Lei, Zhang, Xiao-hua, Sang, Xiao-xue, Luo, Yu-yang, Tian, Yu-mei, Wu, Bin, Liu, Lin, Luo, Zi-qiang, He, Bin, Liu, Wei, Tang, Si-yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485066/ https://www.ncbi.nlm.nih.gov/pubmed/37679587 http://dx.doi.org/10.1038/s41598-023-41933-5 |
Ejemplares similares
-
NMDA Receptor Antagonist Attenuates Bleomycin-Induced Acute Lung Injury
por: Li, Yang, et al.
Publicado: (2015) -
Megakaryocytes participate in the occurrence of bleomycin-induced pulmonary fibrosis
por: Zhou, Yan, et al.
Publicado: (2019) -
Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice
por: Liu, Wei, et al.
Publicado: (2013) -
Kinetic modeling of the sesamin conversion into asarinin in the presence of citric acid loading on Hβ
por: Yu, Qiong, et al.
Publicado: (2022) -
Preparation and Characterization of Solid Acid Catalysts for the Conversion of Sesamin into Asarinin in Sesame Oil
por: Yu, Qiong, et al.
Publicado: (2022)